COVID-19: Some clinical questions after the first 4 months

Eur J Clin Invest. 2020 Jul;50(7):e13326. doi: 10.1111/eci.13326. Epub 2020 Jul 5.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Age Factors
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Vaccines
  • Comorbidity
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / immunology
  • Genetic Predisposition to Disease
  • Humans
  • Lymphohistiocytosis, Hemophagocytic / immunology
  • Pandemics / prevention & control
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control
  • Prognosis
  • Risk Factors
  • SARS-CoV-2
  • Sex Factors
  • Superinfection / epidemiology
  • Viral Vaccines / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • COVID-19 Vaccines
  • Viral Vaccines
  • tocilizumab